MiNK Therapeutics (NASDAQ:INKT – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $9.00 price target on the stock.
MiNK Therapeutics Trading Down 4.5 %
Shares of INKT stock opened at $0.68 on Wednesday. The company’s fifty day simple moving average is $0.79 and its 200-day simple moving average is $0.90. MiNK Therapeutics has a 52 week low of $0.57 and a 52 week high of $1.90. The company has a market cap of $23.55 million, a PE ratio of -1.13 and a beta of 0.06.
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. Equities research analysts expect that MiNK Therapeutics will post -0.33 EPS for the current fiscal year.
Institutional Trading of MiNK Therapeutics
About MiNK Therapeutics
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
See Also
- Five stocks we like better than MiNK Therapeutics
- Differences Between Momentum Investing and Long Term Investing
- Pinterest: Time to Jump Onboard for Long-Term Gains?
- ETF Screener: Uses and Step-by-Step Guide
- 4 Best ETFs for Capitalizing on the Semiconductor Market Surge
- The Significance of Brokerage Rankings in Stock Selection
- These 3 Stocks Just Spiked—Buy the Rally or Sell the News?
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.